CAV1 and neoplasm: Clinical retrospective studies on breast cancer patients focusing on the expression of caveolin-1, which acts as a tumor-suppressing molecule in CAFs, showed 72 months of cancer-specific survival in caveolin-1-positive patients, whereas only 29.5 months in caveolin-1-negative patients [23].